Literature DB >> 27334834

Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia.

Avery Polk1, Ye Lu1, Tianjiao Wang1, Erlene Seymour1, Nathanael G Bailey2, Jack W Singer3, Philip S Boonstra4, Megan S Lim2, Sami Malek1, Ryan A Wilcox5.   

Abstract

PURPOSE: Monocytes and their progeny are abundant constituents of the tumor microenvironment in lymphoproliferative disorders, including chronic lymphocytic leukemia (CLL). Monocyte-derived cells, including nurse-like cells (NLC) in CLL, promote lymphocyte proliferation and survival, confer resistance to chemotherapy, and are associated with more rapid disease progression. Colony-stimulating factor-1 receptor (CSF-1R) regulates the homeostatic survival of tissue-resident macrophages. Therefore, we sought to determine whether CSF-1R is similarly required for NLC survival. EXPERIMENTAL
DESIGN: CSF-1R expression by NLC was examined by flow cytometry and IHC. CSF-1R blocking studies were performed using an antagonistic mAb to examine its role in NLC generation and in CLL survival. A rational search strategy was performed to identify a novel tyrosine kinase inhibitor (TKI) targeting CSF-1R. The influence of TKI-mediated CSF-1R inhibition on NLC and CLL viability was examined.
RESULTS: We demonstrated that the generation and survival of NLC in CLL is dependent upon CSF-1R signaling. CSF-1R blockade is associated with significant depletion of NLC and consequently inhibits CLL B-cell survival. We found that the JAK2/FLT3 inhibitor pacritinib suppresses CSF-1R signaling, thereby preventing the generation and survival of NLC and impairs CLL B-cell viability.
CONCLUSIONS: CSF-1R is a novel therapeutic target that may be exploited in lymphoproliferative disorders, like CLL, that are dependent upon lymphoma-associated macrophages. Clin Cancer Res; 22(24); 6118-28. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27334834      PMCID: PMC5161678          DOI: 10.1158/1078-0432.CCR-15-3099

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  54 in total

1.  Macrophages specifically regulate the concentration of their own growth factor in the circulation.

Authors:  A Bartocci; D S Mastrogiannis; G Migliorati; R J Stockert; A W Wolkoff; E R Stanley
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

2.  Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation.

Authors:  Chris G Mueller; Charlotte Boix; Wing-Hong Kwan; Cécile Daussy; Emilie Fournier; Wolf H Fridman; Thierry J Molina
Journal:  J Leukoc Biol       Date:  2007-06-15       Impact factor: 4.962

3.  Nurse-like cells show deregulated expression of genes involved in immunocompetence.

Authors:  Nupur Bhattacharya; Susanne Diener; Irina S Idler; Judith Rauen; Sarah Häbe; Hauke Busch; Annett Habermann; Thorsten Zenz; Hartmut Döhner; Stephan Stilgenbauer; Daniel Mertens
Journal:  Br J Haematol       Date:  2011-05-25       Impact factor: 6.998

4.  Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury.

Authors:  Zaher A Radi; Petra H Koza-Taylor; Rosonald R Bell; Leslie A Obert; Herbert A Runnels; Jean S Beebe; Michael P Lawton; Seth Sadis
Journal:  Am J Pathol       Date:  2011-05-13       Impact factor: 4.307

5.  An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation.

Authors:  Kelli P A MacDonald; James S Palmer; Stephen Cronau; Elke Seppanen; Stuart Olver; Neil C Raffelt; Rachel Kuns; Allison R Pettit; Andrew Clouston; Brandon Wainwright; Dan Branstetter; Jeffrey Smith; Raymond J Paxton; Douglas Pat Cerretti; Lynn Bonham; Geoffrey R Hill; David A Hume
Journal:  Blood       Date:  2010-08-03       Impact factor: 22.113

6.  Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse.

Authors:  S C Marks; P W Lane
Journal:  J Hered       Date:  1976 Jan-Feb       Impact factor: 2.645

7.  The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment.

Authors:  Andrew J Steele; Archibald G Prentice; Kate Cwynarski; A Victor Hoffbrand; Stephen M Hart; Mark W Lowdell; Edward R Samuel; R Gitendra Wickremasinghe
Journal:  Blood       Date:  2010-08-17       Impact factor: 22.113

8.  Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.

Authors:  Raymond Lai; Susan O'Brien; Taghi Maushouri; Anna Rogers; Hagop Kantarjian; Micheal Keating; Maher Albitar
Journal:  Cancer       Date:  2002-09-01       Impact factor: 6.860

9.  CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Authors:  Antonella Zucchetto; Dania Benedetti; Claudio Tripodo; Riccardo Bomben; Michele Dal Bo; Daniela Marconi; Fleur Bossi; Debora Lorenzon; Massimo Degan; Francesca Maria Rossi; Davide Rossi; Pietro Bulian; Vito Franco; Giovanni Del Poeta; Silvia Deaglio; Gianluca Gaidano; Francesco Tedesco; Fabio Malavasi; Valter Gattei
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

Review 10.  Profile of pacritinib and its potential in the treatment of hematologic disorders.

Authors:  Eleftheria Hatzimichael; Evangelos Tsolas; Evangelos Briasoulis
Journal:  J Blood Med       Date:  2014-08-19
View more
  20 in total

1.  Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Authors:  Stephen E Kurtz; Christopher A Eide; Andy Kaempf; Vishesh Khanna; Samantha L Savage; Angela Rofelty; Isabel English; Hibery Ho; Ravi Pandya; William J Bolosky; Hoifung Poon; Michael W Deininger; Robert Collins; Ronan T Swords; Justin Watts; Daniel A Pollyea; Bruno C Medeiros; Elie Traer; Cristina E Tognon; Motomi Mori; Brian J Druker; Jeffrey W Tyner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-07       Impact factor: 11.205

2.  Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.

Authors:  Carlos Murga-Zamalloa; Delphine C M Rolland; Avery Polk; Ashley Wolfe; Hiran Dewar; Pinki Chowdhury; Ozlem Onder; Rajan Dewar; Noah A Brown; Nathanael G Bailey; Kedar Inamdar; Megan S Lim; Kojo S J Elenitoba-Johnson; Ryan A Wilcox
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

3.  Disruption of Nurse-like Cell Differentiation as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.

Authors:  Giovanna Merchand-Reyes; Ramasamy Santhanam; Frank H Robledo-Avila; Christoph Weigel; Juan de Dios Ruiz-Rosado; Xiaokui Mo; Santiago Partida-Sánchez; Jennifer A Woyach; Christopher C Oakes; Susheela Tridandapani; Jonathan P Butchar
Journal:  J Immunol       Date:  2022-08-22       Impact factor: 5.426

4.  Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.

Authors:  Elias D Bührer; Michael A Amrein; Stefan Forster; Stephan Isringhausen; Christian M Schürch; Salil S Bhate; Tess Brodie; Joel Zindel; Deborah Stroka; Mohamad Al Sayed; César Nombela-Arrieta; Ramin Radpour; Carsten Riether; Adrian F Ochsenbein
Journal:  Leukemia       Date:  2022-09-26       Impact factor: 12.883

Review 5.  B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.

Authors:  G Galletti; F Caligaris-Cappio; M T S Bertilaccio
Journal:  Leukemia       Date:  2016-09-28       Impact factor: 11.528

6.  CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.

Authors:  David K Edwards; Kevin Watanabe-Smith; Angela Rofelty; Alisa Damnernsawad; Ted Laderas; Adam Lamble; Evan F Lind; Andy Kaempf; Motomi Mori; Mara Rosenberg; Amanda d'Almeida; Nicola Long; Anupriya Agarwal; David Tyler Sweeney; Marc Loriaux; Shannon K McWeeney; Jeffrey W Tyner
Journal:  Blood       Date:  2018-11-13       Impact factor: 22.113

Review 7.  Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.

Authors:  Tycel Phillips; Sumana Devata; Ryan A Wilcox
Journal:  J Immunother Cancer       Date:  2016-12-20       Impact factor: 13.751

8.  Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.

Authors:  David K Edwards V; David Tyler Sweeney; Hibery Ho; Christopher A Eide; Angela Rofelty; Anupriya Agarwal; Selina Qiuying Liu; Alexey V Danilov; Patrice Lee; David Chantry; Shannon K McWeeney; Brian J Druker; Jeffrey W Tyner; Stephen E Spurgeon; Marc M Loriaux
Journal:  Oncotarget       Date:  2018-05-15

9.  Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.

Authors:  Jack W Singer; Suliman Al-Fayoumi; Haiching Ma; Rami S Komrokji; Ruben Mesa; Srdan Verstovsek
Journal:  J Exp Pharmacol       Date:  2016-08-16

Review 10.  Targeting tumour microenvironment by tyrosine kinase inhibitor.

Authors:  Hor-Yue Tan; Ning Wang; Wing Lam; Wei Guo; Yibin Feng; Yung-Chi Cheng
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.